Cargando…
Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acut...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078241/ https://www.ncbi.nlm.nih.gov/pubmed/30082349 http://dx.doi.org/10.1136/bmjopen-2017-020941 |
_version_ | 1783345057528545280 |
---|---|
author | Persaud, Nav Laupacis, Andreas Azarpazhooh, Amir Birken, Catherine Hoch, Jeffrey S Isaranuwatchai, Wanrudee Maguire, Jonathan L Mamdani, Muhammad M Thorpe, Kevin Allen, Christopher Mason, Dalah Kowal, Christine Bazeghi, Farnaz Parkin, Patricia |
author_facet | Persaud, Nav Laupacis, Andreas Azarpazhooh, Amir Birken, Catherine Hoch, Jeffrey S Isaranuwatchai, Wanrudee Maguire, Jonathan L Mamdani, Muhammad M Thorpe, Kevin Allen, Christopher Mason, Dalah Kowal, Christine Bazeghi, Farnaz Parkin, Patricia |
author_sort | Persaud, Nav |
collection | PubMed |
description | INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acute otitis media (AOM), a common and costly condition in young children. The primary outcome will be the incidence of AOM. Secondary outcomes will include upper respiratory tract infections (URTIs) and dental caries. METHODS AND ANALYSIS: This study will be a pragmatic, blinded (participant and parents, practitioners and analyst), two-armed superiority, placebo-controlled randomised trial with 1:1 allocation, stratified by clinical site. The trial will be conducted in the 11 primary care group practices participating in the TARGet Kids! research network in Canada. Eligible participants between the ages of 2–4 years will be randomly assigned to the intervention arm of regular xylitol syrup use or the control arm of regular sorbitol use for 6 months. We expect to recruit 236 participants, per treatment arm, to detect a 20% relative risk reduction in AOM episodes. AOM will be identified through chart review. The secondary outcomes of URTIs and dental caries will be identified through monthly phone calls with specified questions. ETHICS AND DISSEMINATION: Ethics approval from the Research Ethics Boards at the Hospital for Sick Children and St. Michael’s Hospital has been obtained for this study and also for the TARGet Kids! research network. Results will be submitted for publication to a peer-reviewed journal and will be discussed with decision makers. TRIAL REGISTRATION NUMBER: NCT03055091; Pre-results. |
format | Online Article Text |
id | pubmed-6078241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-60782412018-08-09 Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial Persaud, Nav Laupacis, Andreas Azarpazhooh, Amir Birken, Catherine Hoch, Jeffrey S Isaranuwatchai, Wanrudee Maguire, Jonathan L Mamdani, Muhammad M Thorpe, Kevin Allen, Christopher Mason, Dalah Kowal, Christine Bazeghi, Farnaz Parkin, Patricia BMJ Open General practice / Family practice INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acute otitis media (AOM), a common and costly condition in young children. The primary outcome will be the incidence of AOM. Secondary outcomes will include upper respiratory tract infections (URTIs) and dental caries. METHODS AND ANALYSIS: This study will be a pragmatic, blinded (participant and parents, practitioners and analyst), two-armed superiority, placebo-controlled randomised trial with 1:1 allocation, stratified by clinical site. The trial will be conducted in the 11 primary care group practices participating in the TARGet Kids! research network in Canada. Eligible participants between the ages of 2–4 years will be randomly assigned to the intervention arm of regular xylitol syrup use or the control arm of regular sorbitol use for 6 months. We expect to recruit 236 participants, per treatment arm, to detect a 20% relative risk reduction in AOM episodes. AOM will be identified through chart review. The secondary outcomes of URTIs and dental caries will be identified through monthly phone calls with specified questions. ETHICS AND DISSEMINATION: Ethics approval from the Research Ethics Boards at the Hospital for Sick Children and St. Michael’s Hospital has been obtained for this study and also for the TARGet Kids! research network. Results will be submitted for publication to a peer-reviewed journal and will be discussed with decision makers. TRIAL REGISTRATION NUMBER: NCT03055091; Pre-results. BMJ Publishing Group 2018-08-05 /pmc/articles/PMC6078241/ /pubmed/30082349 http://dx.doi.org/10.1136/bmjopen-2017-020941 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | General practice / Family practice Persaud, Nav Laupacis, Andreas Azarpazhooh, Amir Birken, Catherine Hoch, Jeffrey S Isaranuwatchai, Wanrudee Maguire, Jonathan L Mamdani, Muhammad M Thorpe, Kevin Allen, Christopher Mason, Dalah Kowal, Christine Bazeghi, Farnaz Parkin, Patricia Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title | Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title_full | Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title_fullStr | Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title_full_unstemmed | Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title_short | Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
title_sort | xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial |
topic | General practice / Family practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078241/ https://www.ncbi.nlm.nih.gov/pubmed/30082349 http://dx.doi.org/10.1136/bmjopen-2017-020941 |
work_keys_str_mv | AT persaudnav xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT laupacisandreas xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT azarpazhoohamir xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT birkencatherine xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT hochjeffreys xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT isaranuwatchaiwanrudee xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT maguirejonathanl xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT mamdanimuhammadm xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT thorpekevin xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT allenchristopher xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT masondalah xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT kowalchristine xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT bazeghifarnaz xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT parkinpatricia xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial AT xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial |